Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › emapalumab

emapalumab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of emapalumab

4 trials tracked of emapalumab: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 526 citations.

4Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 3 Phase 2 1
  1. Phase 3 A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody Completed · 526 cited
  2. Phase 3 Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis Completed
  3. Phase 3 Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE Completed
  4. Phase 2 A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Triple consolidation with CAR T cells yields sustained remission in relapsed BPDCN
Allergy & Immunology Sys. Review
Triple consolidation with CAR T cells yields sustained remission in relapsed BPDCN New treatment strategy shows promise for rare blood cancer
This case report and literature review describes a 55-year-old man with relapsed/refractory BPDCN and CNS involvement who achieved sustained…
A new three-part treatment plan helped a man with a rare, aggressive blood cancer achieve long-term remission when no donor was available.
Frontiers Jul 31, 2026